U.S. markets closed

Pliant Therapeutics, Inc. (PLRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.37-0.13 (-0.53%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close24.50
Open24.41
Bid23.55 x 1000
Ask24.93 x 900
Day's Range24.13 - 24.85
52 Week Range21.05 - 35.63
Volume61,554
Avg. Volume230,000
Market Cap863.77M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results
      PR Newswire

      Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results

      Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second-quarter 2020 financial results.

    • Could This Recent IPO Biotech Become the Next Moderna?
      Motley Fool

      Could This Recent IPO Biotech Become the Next Moderna?

      This question is really less about Moderna's IPO and more about what happened afterward, with the biotech stock tripling in value this year. Pliant Therapeutics (NASDAQ: PLRX) held a successful IPO earlier this month, raising $144 million after originally planning to raise $86 million.

    • Pliant Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares
      PR Newswire

      Pliant Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

      Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the closing of its initial public offering of 10,350,000 shares of common stock, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 1,350,000 shares of common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds to Pliant from the initial public offering were approximately $165.6 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares of common stock were offered by Pliant. The shares began trading on The Nasdaq Global Select Market on June 3, 2020, under the ticker symbol "PLRX."